Talawar Therapeutics to Go Public via SPAC Merger, Secures $225M PIPE to Advance Bispecific Antibody for Atopic Dermatitis
核心洞察
Talawar Therapeutics (搜索) and JATT II Acquisition Corp (搜索) announced a definitive business combination agreement, with the combined company expected to trade on Nasdaq under ticker "TLWR."
The transaction includes an oversubscribed $225 million PIPE led by Access Biotechnology (搜索), with total expected proceeds of $285 million at closing.
Lead candidate TALA-125 (搜索), a novel anti-IL-13 (搜索) × anti-IL-18 (搜索) bispecific antibody for atopic dermatitis (搜索), is expected to enter the clinic in Q1 2027 with Phase 2b data readout in H2 2028.
Talawar Therapeutics (搜索) and JATT II Acquisition Corp (搜索) (Nasdaq: JATT) announced on June 29, 2026 that they have entered into a definitive business combination agreement, creating a publicly listed biotechnology company focused on developing potentially best-in-class bispecific antibodies for immunology and inflammatory (I&I) diseases. The combined company will operate as Talawar Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol "TLWR."
The transaction includes an oversubscribed $225 million concurrent private investment in public equity (PIPE) at $10.00 per share. Upon closing, the combined company expects to receive $285 million, prior to the payment of transaction costs and assuming no redemptions by JATT II's public shareholders. Proceeds will be funded through a combination of $60 million held in JATT II's trust account and the $225 million PIPE. The PIPE is led by founding investor Access Biotechnology (搜索) and includes participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, and other leading healthcare-dedicated investors and mutual funds.
TALA-125 (搜索): A Bispecific Approach to Atopic Dermatitis (搜索)
Talawar's lead program, TALA-125 (搜索), is a novel anti-IL-13 (搜索) × anti-IL-18 (搜索) bispecific antibody being developed for atopic dermatitis (搜索). The molecule is designed to combine two clinically validated, largely orthogonal mechanisms in a single therapy, targeting pathways that work together for greater, more durable impact. Clinical entry for TALA-125 is expected in the first quarter of 2027, with interim Phase 1 data anticipated in the fourth quarter of 2027. Available cash to the combined company at closing is anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028.
"Atopic dermatitis (搜索) remains one of the largest therapeutic markets in I&I, yet a persistent efficacy ceiling leaves a majority of patients unable to achieve meaningful clinical responses on current standard-of-care treatments," said Marc Schegerin, MD, Chief Executive Officer of Talawar. "TALA-125 (搜索) is purpose-built to shatter the current monotherapy efficacy plateau by combining two clinically validated, complementary mechanisms in a single bispecific molecule."
The Khanda Therapeutics (搜索) Model
Talawar is the first company formed to develop and commercialize assets discovered by Khanda Therapeutics (搜索), L.P., a biotech company builder that translates validated and emerging biological insights into biotechnology companies. Khanda's model focuses on uniting orthogonal pathways with rigor and precision to deliver new standards in therapeutic efficacy.
"We set out to build Talawar as Khanda's first company because atopic dermatitis (搜索) represents one of the largest unmet opportunities in I&I, one where the monotherapy paradigm has consistently fallen short for patients," said Dan Becker, MD, PhD, Board Chair of Talawar and Managing Director of Access Biotechnology (搜索). "TALA-125 (搜索) is the embodiment of the Khanda model: uniting two validated, orthogonal pathways in a single molecule to break through the efficacy ceiling where monotherapies have fallen short."
Pipeline and Discovery Programs
Beyond TALA-125 (搜索), Talawar is advancing two discovery-phase programs, TALA-307 and TALA-711, in additional immunology indications. The company's broader strategy involves developing bispecific antibodies that pair independent disease drivers in a single therapy, with broad applicability across first-line patients and those who have failed previous therapies.
Leadership Team
Talawar is led by a team of pharmaceutical industry veterans with deep expertise in I&I. CEO Marc Schegerin, MD, MBA, previously served as COO and CFO at Morphic Therapeutic and as CFO and Head of Strategy at ArQule. Chief Medical Officer Fabio Nunes, MD, MMSc, is an internist and medical geneticist who most recently served as Vice President of Dermatology and Respiratory Clinical Development at Johnson & Johnson, overseeing global Phase 2 and Phase 3 programs.
Praveen Tipirneni, MD, an accomplished biotechnology executive with leadership experience as CEO of Caldera Therapeutics and Morphic Therapeutic, has joined the Talawar Board of Directors.
Transaction Details
The business combination is expected to close in the second half of 2026, subject to customary closing conditions, including approval by JATT II shareholders and regulatory approvals. Guggenheim Securities, Cantor, and LifeSci Capital are serving as placement agents for the PIPE. Cooley LLP is serving as legal counsel to Talawar, while Greenberg Traurig, LLP is serving as legal counsel to JATT II. Davis Polk & Wardwell LLP is serving as legal counsel to the placement agents.